

=> fil reg

FILE 'REGISTRY' ENTERED AT 12:36:12 ON 17 AUG 2006

=> d his ful

FILE 'HCAPLUS' ENTERED AT 10:37:51 ON 17 AUG 2006

L1 1 SEA ABB=ON US20050014220/PN  
SEL RN

FILE 'REGISTRY' ENTERED AT 10:39:10 ON 17 AUG 2006

L2 17 SEA ABB=ON (477950-55-3/BI OR 477950-56-4/BI OR  
477950-57-5/BI OR 477950-58-6/BI OR 477991-18-7/BI OR  
477991-19-8/BI OR 477991-20-1/BI OR 477991-21-2/BI OR  
477994-28-8/BI OR 477994-29-9/BI OR 477994-30-2/BI OR  
477994-31-3/BI OR 477994-32-4/BI OR 477994-33-5/BI OR  
477994-34-6/BI OR 477994-35-7/BI OR 60202-16-6/BI)  
L3 STR  
L4 45 SEA SSS SAM L3  
L5 STR L3  
L6 5 SEA SSS SAM L5  
L7 844 SEA SSS FUL L3  
L8 5 SEA SUB=L7 SSS SAM L5  
L9 0 SEA ABB=ON L7 AND L2  
L10 39 SEA SUB=L7 SSS FUL L5  
SAV L7 HEA360/A  
SAV L10 HEA360A/A

FILE 'HCAPLUS' ENTERED AT 11:45:46 ON 17 AUG 2006


L11 19 SEA ABB=ON L10  
L12 308 SEA ABB=ON L7  
L13 289 SEA ABB=ON L12 NOT L11  
L14 1 SEA ABB=ON US20050004009/PN  
SEL RN

FILE 'REGISTRY' ENTERED AT 12:46:12 ON 17 AUG 2006

L15 28 SEA ABB=ON (286465-43-8/BI OR 286465-44-9/BI OR  
400628-17-3/BI OR 725233-52-3/BI OR 725233-53-4/BI OR  
725233-54-5/BI OR 725233-55-6/BI OR 725233-56-7/BI OR  
725233-57-8/BI OR 725233-59-0/BI OR 725233-60-3/BI OR  
725233-61-4/BI OR 725233-62-5/BI OR 725233-63-6/BI OR  
725233-64-7/BI OR 725233-65-8/BI OR 725233-66-9/BI OR  
725233-67-0/BI OR 725233-68-1/BI OR 751481-25-1/BI OR  
751481-26-2/BI OR 751481-27-3/BI OR 751481-28-4/BI OR  
752718-90-4/BI OR 752718-91-5/BI OR 752718-92-6/BI OR  
752718-93-7/BI OR 752718-94-8/BI)  
L16 22 SEA ABB=ON L7 AND L15  
L17 6 SEA ABB=ON L15 NOT L16

FILE 'HCAPLUS' ENTERED AT 12:47:01 ON 17 AUG 2006

L18 6 SEA ABB=ON L16  
L19 19 SEA ABB=ON L18 OR L11  
L20 73 SEA ABB=ON L13 AND PHARM?/SC,SX  
L21 5 SEA ABB=ON L20 AND PEPTIDOMIMET?  
L22 12 SEA ABB=ON L13 AND PEPTIDOMIMET?  
L23 12 SEA ABB=ON L21 OR L22  
L24 7 SEA ABB=ON L13 AND ?INFLAMM?  
L25 19 SEA ABB=ON L23 OR L24  
L26 797385 SEA ABB=ON CANCER? OR CARCINOMA? OR MELANOMA? OR  
NEOPLAS? OR ?TUMOR? OR ?TUMOUR? OR MALIGNAN?  
L27 20 SEA ABB=ON L20 AND L26



## NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

## GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 25

## STEREO ATTRIBUTES: NONE

L7 844 SEA FILE=REGISTRY SSS FUL L3

L10 39 SEA FILE=REGISTRY SUB=L7 SSS FUL L5

L11 19 SEA FILE=HCAPLUS ABB=ON L10

=&gt; d que 128

L3 STR

## NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

## GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 21

## STEREO ATTRIBUTES: NONE

L5 STR

## NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE

L7 844 SEA FILE=REGISTRY SSS FUL L3  
L10 39 SEA FILE=REGISTRY SUB=L7 SSS FUL L5  
L11 19 SEA FILE=HCAPLUS ABB=ON L10  
L12 308 SEA FILE=HCAPLUS ABB=ON L7  
L13 289 SEA FILE=HCAPLUS ABB=ON L12 NOT L11  
L20 73 SEA FILE=HCAPLUS ABB=ON L13 AND PHARM?/SC, SX  
L21 5 SEA FILE=HCAPLUS ABB=ON L20 AND PEPTIDOMIMET?  
L22 12 SEA FILE=HCAPLUS ABB=ON L13 AND PEPTIDOMIMET?  
L23 12 SEA FILE=HCAPLUS ABB=ON L21 OR L22  
L24 7 SEA FILE=HCAPLUS ABB=ON L13 AND ?INFLAMM?  
L25 19 SEA FILE=HCAPLUS ABB=ON L23 OR L24  
L26 797385 SEA FILE=HCAPLUS ABB=ON CANCER? OR CARCINOMA? OR  
MELANOMA? OR NEOPLAS? OR ?TUMOR? OR ?TUMOUR? OR  
MALIGNAN?  
L27 20 SEA FILE=HCAPLUS ABB=ON L20 AND L26  
L28 32 SEA FILE=HCAPLUS ABB=ON L25 OR L27

=> fil hcap  
FILE 'HCAPLUS' ENTERED AT 12:36:32 ON 17 AUG 2006

=> d l11 1-19 ibib abs hitstr hitind

L11 ANSWER 1 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2006:307869 HCAPLUS  
DOCUMENT NUMBER: 145:483  
TITLE: Selective Inhibition of ErbB2-Overexpressing  
Breast Cancer In vivo by a Novel TAT-Based  
ErbB2-Targeting Signal Transducers and  
Activators of Transcription 3 Blocking Peptide  
AUTHOR(S): Tan, Ming; Lan, Keng-Hsueh; Yao, Jun; Lu,  
Chien-Hsing; Sun, Menghong; Neal, Christopher  
L.; Lu, Jing; Yu, Dihua  
CORPORATE SOURCE: Departments of Surgical Oncology and Molecular  
and Cellular Oncology, The University of Texas  
M.D. Anderson Cancer Center, Houston, TX,  
77030, USA  
SOURCE: Cancer Research (2006), 66(7), 3764-3772  
CODEN: CNREA8; ISSN: 0008-5472  
PUBLISHER: American Association for Cancer Research  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB ErbB2 is an excellent target for cancer therapies. Unfortunately,  
the outcome of current therapies for ErbB2-pos. breast cancers  
remains unsatisfying due to resistance and side effects. New  
therapies for ErbB2-overexpressing breast cancers continue to be  
in great need. Peptide therapy using cell-penetrating peptides  
(CPP) as peptide carriers is promising because the internalization  
is highly efficient, and the cargoes delivered can be bioactive.  
However, the major obstacle in using these powerful CPPs for  
therapy is their lack of specificity. Here, we sought to develop  
a peptide carrier that could introduce therapeutics specifically  
to ErbB2-overexpressing breast cancer cells. By modifying the HIV  
TAT-derived CPP and conjugating anti-HER-2/neu peptide mimetic